We systematically searched PubMed and Embase to include all types of studies on canakinumab treatment in Schnitzler syndrome published until March 16, 2020.
Since 2011, 7 publications have been reported on canakinumab treatment in 34 patients with Schnitzler syndrome. The cumulative follow-up was 253 months, and 5 studies had a follow-up duration of 12 months or more. A complete response during treatment was reported in 58.6% of patients; all other patients had a partial response. Two hundred and seven adverse events were reported in 23 patients. Infection (n = 79) was the most common adverse event. One patient died from sepsis due to atypical mycobacterial infection.
Based on the results of the current systematic review, canakinumab is an effective long-term treatment with a favorable safety profile in patients with Schnitzler syndrome.
我们系统地搜索了PubMed和Embase,以包括直到2020年3月16日发表的关于canakinumab治疗Schnitzler综合征的所有类型的研究。
自2011年以来,已有7篇出版物报道了canakinumab在34例Schnitzler综合征患者中的治疗。累计随访253个月,5项研究的随访时间为12个月或更长时间.据报道,58.6%的患者在治疗期间完全缓解;所有其他患者均有部分缓解。23例患者报告了两百零七个不良事件。感染(n=79)是最常见的不良事件。一名患者因非典型分枝杆菌感染死于败血症。
根据当前系统评价的结果,canakinumab是一种有效的长期治疗方法,对Schnitzler综合征患者具有良好的安全性。